Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07408024 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis

StatusRecruiting
PhasePhase 2
Started2025-09-10
View on ClinicalTrials.gov ↗

Amendment history

2026-10-02
Trial arms changed: 2 → 4
Trial sites reduced: 6 → 1 locations
Interventions modified
2026-02-12
Study Identification, Study Status v1
Study title+14 characters
StudySafety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis
2026-02-05
Original filing
The goal of this study is to evaluate the safety, pharmacokinetic (PK) characteristics, and preliminary efficacy of a new oral chemical drug in : adults aged 18-70 years (male or female) with moderate to severe active rheumatoid arthritis (RA), who have had inadequate response to or intolerance of at least one conventional synthetic disease-modifying antirheumatic drug (csDMARDs) .
Trial Details
NCT Number NCT07408024
Lead Sponsor Toll Biotech Co. Ltd. (Beijing)
Conditions Rheumatoid Arthritis (RA)
Enrollment 24 participants
Start Date 2025-09-10
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-10-01